Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Liver Regeneration01:24

Liver Regeneration

3.3K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
3.3K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

902
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
902
Hepatic Portal System01:21

Hepatic Portal System

1.8K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
1.8K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients.

International journal of cancer·2026
Same author

Trends in the incidence and surgical treatment of hepatocellular carcinoma in Ontario.

Canadian journal of surgery. Journal canadien de chirurgie·2026
Same author

Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

Nature reviews. Clinical oncology·2026
Same author

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Corrigendum to "Direct-acting antivirals lower mortality and recurrence in HCV-related hepatocellular carcinoma post liver resection: A multicenter international study" [Surgery 183 (2025) 109396].

Surgery·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Aug 29, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.3K

肝細胞がん

Arndt Vogel1, Tim Meyer2, Gonzalo Sapisochin3

  • 1Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

Lancet (London, England)
|September 9, 2022
PubMed
まとめ
この要約は機械生成です。

肝細胞癌 (HCC) は,世界的に主要な癌であり,非アルコール性脂肪肝が主要な原因として浮上しています. 治療の進歩により 結果は改善されていますが 最適な薬物配列とバイオマーカーが必要です

さらに関連する動画

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

36.3K

関連する実験動画

Last Updated: Aug 29, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.3K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

36.3K

科学分野:

  • ヘパトロジー
  • 腫瘍学
  • 胃腸内科

背景:

  • 肝細胞癌 (HCC) は,世界中で癌による死亡の主な原因です.
  • ウイルス性肝炎とアルコールは伝統的なリスク因子ですが,非アルコール性脂肪肝はHCCの増加原因です.
  • HCCの管理は,世界的な保健医療における大きな課題です.

研究 の 目的:

  • 肝細胞がん (HCC) の最新版の概要を提示する.
  • HCCの病因,診断,分子分類,現在の治療戦略をカバーする.
  • 先進的なHCCの治療分野における最近の進歩を強調する.

主な方法:

  • 現在の文献と臨床実務ガイドラインのレビュー
  • HCCの病因と治療の新興傾向の分析
  • HCC管理における多学科アプローチの議論

主要な成果:

  • 先進的なHCCの治療は,新しい全身性薬剤と免疫療法によってますます多様化しています.
  • 臨床的意思決定には,多学問的なチームアプローチが必要で,腫瘍の段階,肝機能,およびパフォーマンス状態に基づいて戦略を適応させる必要があります.
  • 治療の進歩により,HCCの患者展望は改善されました.

結論:

  • 治療の最適な配列と予測バイオマーカーの必要性は,HCCの将来の研究にとって重要な分野です.
  • 非アルコール性脂肪肝は,HCCの発症において懸念が高まっている.
  • 継続的な研究と多学科の協力は,HCC患者のアウトカムを改善するために不可欠です.